Vascular cell adhesion molecule 1 in patients with severe osteoarthritis of the hip : A prospective cross-sectional study.
Adult
Aged
Arthroplasty
Biomarkers/blood
CD106
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
24
04
2018
accepted:
03
04
2019
pubmed:
1
5
2019
medline:
17
9
2019
entrez:
1
5
2019
Statut:
ppublish
Résumé
Osteoarthritis (OA) of the hip is a frequent and debilitating joint disease. Only few clinical risk factors for hip OA are established and clinically applicable biomarkers to identify patients at risk are still lacking. The glycoprotein vascular cell adhesion molecule 1 (VCAM-1) is expressed by chondrocytes and synovial tissue and was a predictive marker for development of severe large joint OA in a previous study. It was tested whether increased serum levels of VCAM-1 are prevalent in patients with severe OA of the hips. In this prospective, multicenter, cross-sectional study, risk factors of severe hip OA were investigated in patients scheduled for hip joint arthroplasty and 100 patients were randomly selected for validation of VCAM-1 as a potential biomarker for hip OA. Serum samples were analyzed by an enzyme-linked immunosorbent assay and compared with a sex and age-matched control cohort. The groups were similar in age, gender ratio and prevalence of diabetes. Serum concentrations of VCAM-1 were 8% higher in OA patients compared to controls, without reaching statistical significance (818 ng ml The results of this study show that serum concentrations of VCAM-1 cannot distinguish patients with severe hip OA from age and sex-matched controls.
Sections du résumé
BACKGROUND
BACKGROUND
Osteoarthritis (OA) of the hip is a frequent and debilitating joint disease. Only few clinical risk factors for hip OA are established and clinically applicable biomarkers to identify patients at risk are still lacking. The glycoprotein vascular cell adhesion molecule 1 (VCAM-1) is expressed by chondrocytes and synovial tissue and was a predictive marker for development of severe large joint OA in a previous study.
OBJECTIVE
OBJECTIVE
It was tested whether increased serum levels of VCAM-1 are prevalent in patients with severe OA of the hips.
METHODS
METHODS
In this prospective, multicenter, cross-sectional study, risk factors of severe hip OA were investigated in patients scheduled for hip joint arthroplasty and 100 patients were randomly selected for validation of VCAM-1 as a potential biomarker for hip OA. Serum samples were analyzed by an enzyme-linked immunosorbent assay and compared with a sex and age-matched control cohort.
RESULTS
RESULTS
The groups were similar in age, gender ratio and prevalence of diabetes. Serum concentrations of VCAM-1 were 8% higher in OA patients compared to controls, without reaching statistical significance (818 ng ml
CONCLUSION
CONCLUSIONS
The results of this study show that serum concentrations of VCAM-1 cannot distinguish patients with severe hip OA from age and sex-matched controls.
Identifiants
pubmed: 31037360
doi: 10.1007/s00508-019-1497-2
pii: 10.1007/s00508-019-1497-2
pmc: PMC6702185
doi:
Substances chimiques
Biomarkers
0
Vascular Cell Adhesion Molecule-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
369-373Subventions
Organisme : Austrian Science Fund
ID : KLI 123
Références
Circulation. 2002 Feb 19;105(7):804-9
pubmed: 11854119
Shock. 2003 May;19(5):448-51
pubmed: 12744488
J Immunol. 1992 Aug 15;149(4):1424-31
pubmed: 1380043
Bull World Health Organ. 2003;81(9):646-56
pubmed: 14710506
Arthritis Rheum. 2006 Jan;54(1):226-9
pubmed: 16385518
Int J Obes (Lond). 2006 Aug;30(8):1176-82
pubmed: 16520813
Nat Clin Pract Rheumatol. 2007 Feb;3(2):78-85
pubmed: 17299445
Osteoarthritis Cartilage. 2009 Feb;17(2):168-73
pubmed: 18760940
Arthritis Rheum. 2009 Aug;60(8):2381-9
pubmed: 19644856
Ann Rheum Dis. 2010 Aug;69(8):1573-4
pubmed: 20388743
Antioxid Redox Signal. 2011 Sep 15;15(6):1607-38
pubmed: 21050132
Nat Rev Rheumatol. 2011 Jan;7(1):33-42
pubmed: 21119608
Clin Exp Rheumatol. 2011 May-Jun;29(3):544-6
pubmed: 21640050
Rheumatology (Oxford). 2013 Feb;52(2):400-2
pubmed: 23173188
Nat Rev Rheumatol. 2013 Apr;9(4):225-35
pubmed: 23247649
Wien Med Wochenschr. 2013 May;163(9-10):206-11
pubmed: 23377950
Ann Rheum Dis. 2013 Dec;72(12):2006-10
pubmed: 23599437
Rheumatology (Oxford). 2015 Sep;54(9):1692-8
pubmed: 25953699
BMJ Open. 2015 Sep 29;5(9):e007609
pubmed: 26419679
RMD Open. 2015 Jun 02;1(1):e000077
pubmed: 26535137
Cell. 1989 Dec 22;59(6):1203-11
pubmed: 2688898
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663
Adv Ther. 2016 Nov;33(11):1921-1946
pubmed: 27671326
J Clin Anesth. 2016 Nov;34:232-8
pubmed: 27687381
Evid Based Complement Alternat Med. 2016;2016:7242478
pubmed: 27807463
Medicine (Baltimore). 2016 Nov;95(46):e5384
pubmed: 27861372
J Am Coll Cardiol. 2017 May 9;69(18):2348-2350
pubmed: 28473143
Adv Exp Med Biol. 2017;960:345-379
pubmed: 28585207
Osteoarthritis Cartilage. 2018 Mar;26(3):356-362
pubmed: 29258881
Life Sci. 1996;58(23):2167-81
pubmed: 8649201
Life Sci. 1996 May 24;58(26):2377-87
pubmed: 8691982
Circulation. 1997 Dec 16;96(12):4219-25
pubmed: 9416885
Arthritis Rheum. 1998 Jul;41(7):1296-305
pubmed: 9663488